26 RESULTS
Go to another page:
COMMENT This very nice and extensively documented report demonstrates the efficacy of a new small molecule (DAPPD) that inhibits NF-κB pathway-mediated activation of microglia by Aβ to restore microglial amyloid clearance in two lines of APP/PS1 mutant mice. They ...
COMMENT The INTREPAD trial is notable as a follow-up to questions raised by the ADAPT naproxen trial, e.g., if starting patients earlier, prior to any decline, and treating for a full two years with 400 mg naproxen daily can impact rates of decline and/or tau ...
COMMENT In a nutshell, supplement manufacturers frequently make claims, either directly or through leaflets and media campaigns, that wildly overstate the evidence for efficacy. The most egregiously successful advertise about the benefits of orally delivered ...
COMMENT Given that anti-Aβ immunotherapy induces amyloid phagocytosis and clearance and is being tested in the clinic, the mechanisms that limit natural clearance via this pathway are obviously important. This paper is data-rich and makes a number of interesting ...
COMMENT This is a very interesting initial look at a new model with selective brain ApoE KO that still shows some synaptic deficits but not the supposedly related cognitive deficits. The authors view this as entirely due to correction of peripheral hyperlipidemia ...
COMMENT The APP-KI mouse model is valuable in that it avoids the impact of chronic high overexpression of APP that signals through sAPPα and a multitude of APP binding proteins, most obviously those that interact with the C terminal cytoplasmic domain when it is ...
COMMENT I see several issues related to the AREDS2 trial that weaken the generalizability of this type of study's negative conclusions. The authors point to cardiovascular disease as one likely cause of cognitive decline in the overall population. For ...
COMMENT I found this paper both convincing and very interesting because: 1) The in vitro results provide a specific mechanism for an APP-dependent but Aβ-independent toxicity pathway via β-CTF recruitment of Rab5 and APPL1 to the endosomal\lysosomal system. 2) ...
COMMENT In general, this is a very sophisticated and admirable study. Small and colleagues have developed a functional novel-object-recognition test (ModBent) that maps to a dependence on a specific anatomical compartment, the dentate gyrus of the hippocampus. ...
COMMENT This study has large enough subject numbers in prospective cohorts with long follow-up (eight to 24 years) to be able to detect reduced ALS diagnosed at death in those with higher total dietary omega-3. This long follow-up is extremely important if you ...
COMMENT Reply to comment by Diane Stephenson In general, the recent GWAS data provide a compelling rationale for some causal modulatory role for the immune system in the development of AD. But they don't clarify what this role is. It may be a positive role ...
COMMENT This paper by Massone and colleagues is intriguing in that they report that IL1-α elevates 38A RNA in a cyclo-oxygenase (COX) inhibitor-sensitive manner, and that AD brain has markedly elevated 38A RNA consistent with an inflammation-driven increase. They ...
COMMENT This fairly comprehensive new study from Calon’s group is notable in demonstrating in vivo electrophysiological and biochemical deficits in entorhinal cortex (EC) of LaFerla’s triple Tg mice that can be ameliorated, along with memory deficits, by dietary ...
COMMENT It is intriguing that SorCS1 (see AlzGene) has gender differences in functional effects on Aβ production as well as in the Liang et al., 2009, linkage study. Of course, it makes sense in that it ties into the overall story that genetic differences that ...
COMMENT This fly paper catches genetic evidence that Rac inhibition slows memory decay, constitutively increased Rac activation accelerates memory decay, and that cofilin hyperactivation gives rise to the same phenotype as seen with Rac inhibition. The authors ...
Go to another page:
